These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36271137)

  • 1. Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria.
    Lee HJ; Noh HK; Joo JK
    Sci Rep; 2022 Oct; 12(1):17723. PubMed ID: 36271137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
    Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
    Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients.
    Guo Y; Jiang H; Hu S; Liu S; Li F; Jin L
    J Ovarian Res; 2021 Aug; 14(1):111. PubMed ID: 34454544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between the modified long gonadotropin-releasing hormone agonist protocol and the non-downregulation protocol in POSEIDON groups: a propensity score matching retrospective cohort study.
    Chen C; Zeng X; Zhang H; Wei Q; Gao Y; Liu L
    Front Endocrinol (Lausanne); 2023; 14():1189357. PubMed ID: 38027212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative live birth rates in low-prognosis women.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
    Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we overlook predictive factors in Poseidon 1 patients? A retrospective analysis co-evaluating antral follicle counts & diameters.
    Uncu G; Aslan K; Cakir C; Avci B; Kasapoglu I; Alviggi C
    J Ovarian Res; 2024 Jan; 17(1):1. PubMed ID: 38169411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Factors for Live Birth in Fresh
    Li F; Ye T; Kong H; Li J; Hu L; Jin H; Guo Y; Li G
    Front Endocrinol (Lausanne); 2021; 12():630832. PubMed ID: 33967954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: A retrospective study according to the POSEIDON criteria.
    Farimani M; Nazari A; Mohammadi S; Anvari Aliabad R
    Reprod Biol Endocrinol; 2021 Sep; 19(1):137. PubMed ID: 34496887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-Müllerian hormone on early pregnancy loss in hormone replacement therapy-frozen-thawed embryo transfer cycles: An analysis including 6597 pregnant patients undergoing their first in vitro fertilization/intracytoplasmic sperm injection cycle.
    Xie H; Cheng T; Yuan F; Zhang C; He Q
    Int J Gynaecol Obstet; 2024 Sep; 166(3):1183-1190. PubMed ID: 38563796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria.
    Liu X; Xu J; Bi L; Liu P; Jiao X
    Front Endocrinol (Lausanne); 2021; 12():790160. PubMed ID: 34925245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Anti-Müllerian Hormone and
    Sun XY; Lan YZ; Liu S; Long XP; Mao XG; Liu L
    Front Endocrinol (Lausanne); 2020; 11():595448. PubMed ID: 33343511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of anti-Mullerian hormone for pregnancy outcomes following assisted reproductive techniques (ART) in Southwest China.
    Liu L; Sun XY; Yang H; Feng XJ; Lan YZ
    Reprod Health; 2022 Dec; 19(1):224. PubMed ID: 36514055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
    Front Endocrinol (Lausanne); 2021; 12():630550. PubMed ID: 33790862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of type 2 diabetes mellitus on ovarian reserve and pregnancy outcomes during the assisted reproductive technology process.
    Qin X; Du J; He R; Li Y; Zhu Q; Li Y; Li H; Liang X
    Front Endocrinol (Lausanne); 2023; 14():1274327. PubMed ID: 38033999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study.
    Zhang S; Yin Y; Li Q; Zhang C
    Front Endocrinol (Lausanne); 2021; 12():644456. PubMed ID: 34234739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management Strategies for POSEIDON Group 2.
    Sunkara SK; Ramaraju GA; Kamath MS
    Front Endocrinol (Lausanne); 2020; 11():105. PubMed ID: 32174892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles.
    Dai X; Wang Y; Yang H; Gao T; Yu C; Cao F; Xia X; Wu J; Zhou X; Chen L
    Sci Rep; 2020 Nov; 10(1):19750. PubMed ID: 33184364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].
    Li Y; Tan JQ; Mai ZY; Yang DZ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jan; 53(1):23-30. PubMed ID: 29374882
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis.
    Du M; Zhang J; Li Z; Liu X; Li J; Liu W; Guan Y
    Front Endocrinol (Lausanne); 2021; 12():705264. PubMed ID: 34589055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.